The landscape of dementia prognosis has developed substantially with the appearance of refined biomarkers, such as amyloid PET scans, tau imaging, and blood-dependent checks which will detect Alzheimer's pathology several years before signs or symptoms arise. Whilst these technological improvements signify extraordinary progress in knowing neurodeg